Core Insights - 康恩贝's stock price increased by 2.19% on October 31, reaching 4.66 CNY per share, with a trading volume of 275 million CNY and a market capitalization of 11.766 billion CNY [1] - The company reported a year-to-date stock price increase of 3.23%, with a 4.25% rise over the last five trading days and a 6.88% increase over the last 20 days [1] - For the period from January to September 2025, 康恩贝 achieved a revenue of 4.976 billion CNY, reflecting a year-on-year growth of 1.27%, and a net profit attributable to shareholders of 584 million CNY, up 12.65% year-on-year [2] Financial Performance - 康恩贝's main business revenue composition includes 52.80% from traditional Chinese medicine, 35.68% from specialty chemical drugs, 9.56% from specialty health products, and 1.30% from other supplementary products [1] - Cumulative cash dividends paid by 康恩贝 since its A-share listing amount to 3.727 billion CNY, with 1.267 billion CNY paid out in the last three years [3] Shareholder Structure - As of September 30, 2025, 康恩贝 had 86,700 shareholders, a decrease of 3.48% from the previous period, with an average of 29,037 circulating shares per shareholder, an increase of 1.20% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 50.739 million shares, an increase of 23.964 million shares from the previous period [3]

证券代码：600572 证券简称：康恩贝 公告编号：临 2025-043 浙江康恩贝制药股份有限公司 关于公司 2025 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 浙江康恩贝制药股份有限公司（以下简称"公司"）根据上海证券交易所发布 的上市公司分行业信息披露指引《上市公司行业信息披露指引第六号——医药制造》 及《关于做好上市公司 2025 年半年度报告披露工作的通知》相关要求，现将公司 2025 年半年度主要经营数据披露如下： 一、报告期内分行业经营数据 | 分治疗 | 营业收入 | 营业成本 | 毛利率 | 营业收入 比上年增 | 营业成本比 上年增减 | 毛利率比上 | | --- | --- | --- | --- | --- | --- | --- | | 领域 | | | (%) | 减（%） | （%） | 年增减（%） | | 心血管系统 | 26,962.58 | 9,145.83 | 66.08 | -6.15 | -0.53 | 减少1.92个百 分点 | | 生殖泌尿系统 ...